drugset / Trial / NCT00525902
Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
Phase 2
Completed
31 enrolled
Oregon Health and Science University
The Cleveland Clinic · collabUniversity of Illinois at Chicago · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |